MAZE
Maze Therapeutics, Inc.
36.73
+1.28 (+3.61%)
52w low 21.95
53.65 high
46.6% of range
Financial Analysis
| (USD) | Dec 22 | Dec 23 | Dec 24 | Dec 25 | Trend |
|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 167.50M | 0.00 | |
| Operating Expenses | 111.03M | 98.55M | 109.91M | 142.90M | |
| R&D | 88.19M | 73.94M | 83.50M | 108.45M | |
| SG&A | 22.83M | 24.61M | 26.42M | 34.45M | |
| Operating Income | -111.03M | -98.55M | 57.59M | -142.90M | |
| EBITDA | -107.21M | -94.46M | 60.88M | -140.50M | |
| Pretax Income | -114.94M | -100.42M | 53.40M | -131.12M | |
| Income Tax | -- | 0.00 | 1.17M | 0.00 | |
| Net Income | -114.94M | -100.42M | 52.23M | -131.12M | |
| EPS Diluted | -3.29 | -2.87 | 0.08 | -3.05 | |
| Diluted Shares | 35.40M | 35.40M | 43.78M | 42.98M |
Revenue CAGR
--
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
-100.0%